Prelude Capital Management’s Moderna MRNA Stock Holding History

Prelude Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$471K	Buy	+6,725	New	+$348K	0.03%	552
2026 Q1	–	Sell	-7,095	Closed	-$209K	–	1453
2025 Q4	$209K	Buy	+7,095	New	+$193K	0.02%	1037
2021 Q2	–	Sell	-4,159	Closed	-$743K	–	1846
2021 Q1	$545K	Sell	4,159 -5,741	-58%	-$832K	0.01%	861
2020 Q4	$1.03M	Buy	9,900 +8,941	+932%	+$905K	0.03%	473
2020 Q3	$68K	Buy	+959	New	+$66.9K	﹤0.01%	1036
2020 Q1	–	Sell	-12,423	Closed	-$286K	–	1819
2019 Q4	$243K	Buy	+12,423	New	+$220K	0.01%	797
2019 Q2	–	Sell	-8,541	Closed	-$174K	–	1971
2019 Q1	$174K	Buy	8,541 +3,397	+66%	+$63K	0.01%	759
2018 Q4	$79K	Buy	+5,144	New	+$84.5K	0.01%	1002

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Prelude Capital Management's MRNA Position: Q2 2026 in Review

Prelude Capital Management opened a new position in Moderna (MRNA) in Q2 2026: 6,725 shares worth $471K. The stake represents 0.03% of the portfolio and ranks #552 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in MRNA as recently as Q4 2025.

Prelude Capital Management first reported a position in MRNA in Q4 2018 and has held it in 8 quarters since. The position peaked at $1.03M in Q4 2020. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Prelude Capital Management held 6,725 shares of Moderna worth $471K as of Q2 2026.
Moderna was a new Prelude Capital Management position in Q2 2026.
Moderna made up 0.03% of Prelude Capital Management's portfolio in Q2 2026, its #552 holding.
Prelude Capital Management first reported a position in Moderna in Q4 2018 and has held it in 8 quarters since.
Prelude Capital Management's Moderna position peaked at $1.03M in Q4 2020.
783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.